Role of vildagliptin and its combination in type 2 diabetes mellitus management: a knowledge, attitude, and practice survey among Indian healthcare professionals
DOI:
https://doi.org/10.18203/2320-6012.ijrms20241968Keywords:
Diabetes, KAP survey, Vildagliptin, Metformin, DPP4 inhibitors, IndiaAbstract
Background: Type 2 diabetes mellitus (T2DM) is a prevalent condition, with a significant burden in India, affecting approximately 74.2 million individuals. Vildagliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, is approved globally for monotherapy and combination therapy. Recently, it became available as a generic product, which increased its accessibility to patients. This study aimed to assess the knowledge, attitude, and practice (KAP) regarding vildagliptin and its combination in T2DM management.
Methods: A pan-India cross-sectional KAP survey was conducted from February 2022 to March 2023. The survey utilized a specially designed questionnaire focusing on various aspects of vildagliptin treatment. A total of 1,440 healthcare professionals (HCPs) with recognized qualifications and experience in diabetes management participated. Descriptive statistics were employed for data analysis.
Results: HCPs reported initiating Vildagliptin monotherapy at an HbA1c 6.5-7.5%, while combination therapy with vildagliptin and metformin at HbA1c 7-8%. Vildagliptin was primarily preferred as an add-on to metformin. Inadequate HbA1c control with existing therapy emerged as the primary trigger for switching to vildagliptin and metformin combination. Treatment-naïve T2DM patients with HbA1c 1.5% above target and those uncontrolled on metformin monotherapy or dual therapy were reported to benefit most from combination therapy. Combination therapy was reported to result in a glycemic reduction of 1.0-1.5%. HCPs perceived vildagliptin better than other DPP4 inhibitors due to its efficacy in reducing HbA1c and a lower risk of hypoglycemia.
Conclusions: The KAP survey highlights the value Indian HCPs place on the effectiveness and tolerability of vildagliptin and their attitudes and practices in its use, highlighting its clinical utility in routine practice.
Metrics
References
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81.
World Health Organization. The top 10 causes of death. Available at: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed on 06 March 2024.
Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys. 2015;73(1):181-5.
Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-8.
Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71(7):816-24.
IDF Diabetes Atlas 10th edition. Available at: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf. Accessed on 06 March 2024.
Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2014;74(5):587-610.
Stamataros G, Schneider SH. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12(12):1967-73.
Samraj GP. Vildagliptin for the treatment of diabetes. Clin Pract. 2011;8(6):703.
Das S, Gupta AK, Bandyopadhyaya B, Darla BH, Arya V, Abhyankar M, et al. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management. Bioinformation. 2021;17(3):413-23.
Kalra S, Zargar AH, Sridhar GR, Das AK, Ahmed J, Mohan JC, et al. Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective. Clin Med Insights Endocrinol Diabetes. 2024;17:11795514231203911.
Samajdar SS, Mukherjee S, Sarkar S, Sen S, Tripathi SK, Joshi SR. Availability of different branded generic vildagliptin after off-patenting: An observation from India. J Diabetol. 2023;14:236-8.
Shah AP, Parmar SA, Ramkishan A, Mehta AA. Knowledge, attitude, and practice (KAP) survey regarding the safe use of medicines in rural area of Gujarat. Adv Trop Med Pub Health Int. 2011;1(2):66-70.
Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019;10:389.
Van Gaal L, Hermans MP, Daci E, Denhaerynck K, De Meester L, MacDonald K, et al. Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study. Diabetes Ther. 2019;10(3):965-79.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29(5):305-40.
Das AK, Saxena G, Naik S. HbA1C in Management of Type II Diabetes Mellitus: A Cross-sectional Survey of Indian Physicians. J Assoc Physicians India. 2019;67(7):18-21.
Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(8):675-82.
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132-8.
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047-56.
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-66.
Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, Sethi B, et al. Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study. Diabetes Metab Syndr Obes. 2021;14:2925-33.
Esposito K, Chiodini P, Maiorino MI, Capuano A, Cozzolino D, Petrizzo M, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892.
Chudiwal TB. Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity. Int J Basic Clin Pharmacol. 2017;6:1682-8.
Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5(3):138-46.
Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metabolism. 2011;15(4):298-308.
Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011;59(2):237-45.
Ding Y, Liu Y, Qu Y, Lin M, Dong F, Li Y, et al. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(8):2802-17.
Maladkar M, Sankar S, Darshanwad M. The Journey of Vildagliptin: From Bench to Bedside. The Indian Practitioner. 2022;75(4):28-36.
Pan C, Wang X. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Mana.g 2013;9:247-57.
Rosenstock J, Fitchet M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. Int J Clin Pract Suppl. 2008;159:15-23.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(1):S158-78.
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29.
Summary of product characteristics. Available at Galvus, INN-vildagliptin (europa.eu). Accessed on 16 April 2024.
Kumar S. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. Indian J Endocrinol Metab. 2021;25(4):326-31.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-5.
Hirao K, Maeda H, Shirabe S, Yamamoto R, Hirao T, Hirao S, et al. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus. Jpn Clin Med. 2012;3:1-7.
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28(11):1352-61.
Henness S, Keam SJ. Vildagliptin. Drugs. 2006;66(15):1989-2001.
Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, et al. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. Diabetes Res Clin Pract. 2015;109(1):141-8.
Downloads
Published
How to Cite
Issue
Section
